BRISTOL MYERS SQUIBB CO (BMY)
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults
📈 **POSITIVE** • High confidence analysis (81%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business